Financial buyers, which include real estate investment trusts and private equity firms, are not the dominant players in the health care M&A market. Their participation depends on many factors, with valuations being an important determinant, (see chart below).
In the first quarter of 2017, pharmaceutical deals dropped even further, compared with the previous quarter, and the same quarter the year before.
The first quarter results for the Medical Device sector showed slowing deal volume. A handful of big deals meant spending showed a slight gain.
Hospital deal volume in the first quarter of 2017 slipped further on concerns about repealing the Affordable Care Act.
Biotechnology deal activity has climbed steadily over the past five quarters. The sector reached 62 transactions in Q1:17, an increase of 13% over the previous quarter and up 94% year-over-year. The total is 31% of the 203 deals announced in the previous 12 months. M&A in this sector will remain active for years to come, […]
Deal volume has trended downward in 2016, after spiking in the second quarter with a total of 421 deals.
Brace yourself. The third quarter results for health care mergers and acquisitions signal a hard tap on the brakes, both in deal volume and value. That’s compared with the robust second quarter, and the same quarter a year ago. Before we go any further, though, we must note that, compared with all previous third quarters […]
There’s still one week left to go in the month of September, and the third quarter, but the trends have already established themselves. Merger and acquisition activity in health care dropped 20% compared with the previous quarter, down to 331 deals compared with 415 in Q2:16. The third quarter also pales in comparison to the same […]